Ann: Quarterly Activities Report, page-67

First 67 Last

Share
Profile

Follow
watercooled

484 Posts.

14

02/05/21

13:22

Post #: 52876958
Share

Originally posted by Pharvest ↑

Good on you E you've done very well to recognise the potential like you have. I, like Charles have been continually reassessing and revising my strategy. I'm still all in at this stage and can see things staying that way for at least the rest of the year.

I have only after recent developments come to assess the battery tech as something that is definitely going to bear fruit for the company if i'm honest. I was always more about life sciences and saw batteries as an outside chance. Well the last two battery announcements have changed all that! The CRC seems almost completely centred around our technology and the revelation that collaborator 8 ( Panasonic?? ) have replicated our amazing results and the two companies are talking about a pathway to commercialisation this year... well that means i'm all in for that to come about... won't be selling any for a while yet, no siree , I can ride this up the higher peaks and down a few low dips too, I think there's a lot of us that have become really good at that over the past 18 months, yes is a bit of a nerve wracking emotional roller coaster but if you believe the Anteo SP will be in multiple dollars in under two years why sell yourself short??

A share price over $2 will get me and the Chef ( not sexist, she's a professional Chef lol ) our dream home in Sydney and a holiday home in Lake Tekapo and I'll be able to hold several million of my precious shares long-long term because, well... dividends!

Is all this wanting and expecting too much?
I really don't think it is.. I've got through to nearly 50 without ever owning a place. I've worked underground all over Australia for more than twenty years I've had a couple of nice Holden's in that time but both were sold to buy ADO shares... aside from my favourite pass time of pissing it all up the wall every chance i got until getting sober two years ago everything has gone on ADO.

I have some very well meaning people in my life who know all this and few have been advising me to sell and do this and that with it because they see one strategy or another as being 'safer' but none of them to me understand the potential here with Anteotech.. and as far as risk goes... the huge risk I took was buying the 1 and 1.5c shares in the last couple of capital raises .. that was a huge risk, where's the huge risk now? For me where we are now it's all massive upside and only about just how fast the rate of ascent is going to be!

GLTA

Expand

Hell of a soul share Pharvest. Well done and all future rewards well deserved.

Don't post much here but been in for many years as well and love'n the feeling of vindication.

ADO Price at posting: 43.5¢ Sentiment: Hold Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 22 more messages in this thread...

First 67 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.001(4.76%)		Mkt cap ! $54.77M

Open	High	Low	Value	Volume
2.1¢	2.2¢	2.1¢	$21.58K	1.020M

Buyers (Bids)

No.	Vol.	Price($)
1	100000	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	378168	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.021
10	1443457	0.020
10	2127381	0.019
5	1657002	0.018
4	1574748	0.017

Price($)	Vol.	No.
0.022	378168	5
0.023	642868	9
0.024	141966	2
0.025	478846	7
0.026	83915	2

Last trade - 16.10pm 07/10/2024 (20 minute delay)

ADO (ASX) Chart

Ann: Quarterly Activities Report, page-67

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities Report, page-67

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News